Compare CALC & GFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALC | GFAI |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.2M |
| IPO Year | 2020 | 2020 |
| Metric | CALC | GFAI |
|---|---|---|
| Price | $1.08 | $0.22 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | 56.0K | ★ 154.6K |
| Earning Date | 11-11-2026 | 09-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.88 |
| Revenue Next Year | N/A | $5.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $0.19 |
| 52 Week High | $72.00 | $1.14 |
| Indicator | CALC | GFAI |
|---|---|---|
| Relative Strength Index (RSI) | 23.53 | 22.03 |
| Support Level | $0.44 | N/A |
| Resistance Level | $2.31 | $0.41 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 0.00 | 11.21 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific region. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, and Corporate and others. The majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions. Geographically, the company generates maximum revenue from Thailand.